胆管癌双介入治疗的临床研究

Clinical study of the treatment with double interventional therapy in cholangiocarcinoma

目的探讨经皮经肝穿刺胆道引流(PTBD)联合肝动脉灌注化疗即双介入疗法在肝门部胆管癌的治疗价值。方法24例确诊为肝门部胆管癌的患者,先行PTBD减黄1～2周后行肝动脉灌注化疗(TAI),同期23例肝门部胆管癌患者单纯行PTBD,观察再梗阻时间及生存期。结果双介入组平均存活11月,单纯引流组平均存活5月,主要死因为胆道再梗阻。结论PTBD联合肝动脉灌注化疗(双介入)能明显延长再梗阻发生时间,从而提高患肝门部胆管癌者的生存期。

Objective： To evaluate the clinical value of double interventional therapy in Hilar cholangiocarcinoma. Method： Twenty-four cases diagnosed with Hilar cholangiocarcinoma received PTBD and 1 or 2 weeks later TAI, and simultaneously 23 cases were treated only by PTBD. The re-obstructive time and survival time were observed. Result： The mean survival time of double interventional group was 11 months and the only drainage group was 5 months. The primary cause of death was biliary re-obstructive. Conclusion： PTBD combined TAI（ double interventional）can obviously prolong the re-obstructive time and increase the survival time.